Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer

Table 1 Patient baseline characteristics n (%)

Characteristics	Value
n	40
Age (yr), median (range)	55.50 (26-76)
Gender
Male	22 (55.0)
Female	18 (45.0)
Primary tumor location
Colon cancer	10 (25.0)
Rectal cancer	30 (75.0)
ECOG
0-1	31 (77.5)
≥ 2	9 (22.5)
Metastatic sites
Liver only	6 (15.0)
Lung only	4 (10.0)
Liver and lung only	8 (20.0)
2 sites, including liver or lung	6 (15.0)
2 sites, excluding liver and lung	2 (5.0)
≥ 3 sites	9 (22.5)
1 site, excluding liver and lung	5 (12.5)
Number of metastatic sites
1 site	15 (37.5)
≥ 2 sites	25 (62.5)
Histologic type
Well	9 (22.5)
Moderate	9 (22.5)
Poor	1 (2.5)
Unknown	21 (52.5)
Previous chemotherapy
Fluoropyrimidine + oxaliplatin	31
Fluoropyrimidine + irinotecan	25
Capecitabine combined	15
Fluoropyrimidine combined	6
Line number of bevacizumab
2nd line	17 (42.5)
3rd line	13 (32.5)
4th or later-line	10 (25.0)
Chemotherapy associated with bevacizumab
Oxaliplatin-combined	12 (30.0)
Irinotecan- combined	19 (47.5)
5-fluorouracil-combined	8 (20.0)
Bevacizumab alone	1 (2.5)

ECOG: Performance status score.

Table 2 Response to treatment n (%)

Response	Patients	CR	PR	SD	PD	Unknown
Overall	40	0 (0.0)	3 (7.5)	21 (52.5)	15 (37.5)	1 (2.5)
2nd line	17	0 (0.0)	2 (13.3)	11 (64.7)	4 (23.5)	0 (0.0)
3rd line	13	0 (0.0)	1 (7.7)	6 (46.2)	5 (38.5)	1 (7.7)
4th or later-line	10	0 (0.0)	0 (0.0)	4 (40.0)	6 (60.0)	0 (0.0)

CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease.

Table 3 Analysis of survival

End point	Median follow-up duration (range) (mo)	mOS (95% CI) (mo)	mPFS (95% CI) (mo)
Overall	23.87 (6.13-77.83)	14.00 (7.77-20.23)	6.13 (3.94-8.33)
2nd line	22.37 (6.13-56.10)	16.60 (3.22-29.98)	7.23 (6.45-8.02)
3rd line	20.03 (13.87-57.77)	14.07 (6.89-21.25)	7.30 (3.84-10.77)
4th and later-line	51.12 (17.87-77.83)	13.00 (4.48-21.52)	3.87 (2.78-4.95)

mOS: Median overall survival; mPFS: Median progression-free survival; median follow-up duration: From diagnosis to last follow-up date or death date. CI: Confidence interval.

Table 4 Summary of the data after bevacizumab-combined chemotherapy as second- and later-line treatment in patients with metastatic colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil

Ref.	Treatment line	Treatment regimen	n	ORR (%)	Median PFS (mo)	Median OS (mo)
Giantonio et al[12]	Second	BV + FOLFOX4	287	22.7	7.3	12.9
		FOLFOX4	285	8.6	4.7	10.8
		BV	234	3.3	2.7	10.2
Yildiz et al[20]	Second	BV + Irinotecan-based therapy	40	20.0	6.0	14.0
Chen et al[14]	Third	BV + FU/LV	100	4.0	3.7	9.1
Kwon et al[21]	Third	BV + FOLFIRI	14	28.5	3.9	10.9
Lièvre et al[22]	Second or later-line	BV + FOLFIRI or FOLFOX	31	32.2	9.7	18.4
Kang et al[16]	Third or later-line	BV + FOLFIRI or FOLFOX	42	9.5	5.3	9.5
Park et al	Second or later-line	BV + FOLFIRI or FOLFOX	40	7.5	6.13	14.0

BV: Bevacizumab; FOLFOX4: Fluoropyrimidine + oxaliplatin; FOLFIRI: Fluoropyrimidine + irinotecan; FU/LV: Fluoropyrimidine + leucovorin; OS: Overall survival; PFS: Progression-free survival; ORR: Overall response rate.